News Overview

The 34.5% year on year increase in revenue to ₹390 crore from Indian operations was the main contributor to revenue growth.

EBITDA surged to ₹600.3 crore, up from a loss of ₹208.7 crore in the year-ago quarter, indicating better operational efficiency

The US market is a key growth driver for the company, accounting for almost 47% of Zydus Lifesciences' revenue.

Net Interest Income (NII) slightly reduced by 0.5% to ₹480 crore as against ₹482 crore in Q3 FY24

Gross booking revenue in Q3 FY25 was ₹2,148.9 crore, indicating demand in the travel sector remained strong.

EBITDA was up 14.8% and stood at ₹635 crore compared to ₹553.2 crore, indicating improved operational performance.

Revenue fell by 2.6% year-on-year to ₹4,567.4 crore against ₹4,689.3 crore in Q3 FY24, indicating a marginal slowdown in business activity.

Following an inspection carried out from Nov 14-22 2024, the facility was cited as being ‘VAI’ (Voluntary Action Indicated).

In Q3 FY25, BHEL reported a 170% YoY increase in net profit, reaching ₹124 crore, while revenue grew 32% YoY to ₹7,277 crore, reflecting strong financial performance.

The company reported an 11.6% YoY de-growth in the same to ₹170 crore versus ₹192.2 crore in Q3 FY24.